Bank of New York Mellon Corp Grows Position in Natera, Inc. (NASDAQ:NTRA)

Bank of New York Mellon Corp grew its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 0.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 392,711 shares of the medical research company’s stock after purchasing an additional 3,051 shares during the period. Bank of New York Mellon Corp owned approximately 0.35% of Natera worth $21,803,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Torray Investment Partners LLC boosted its holdings in Natera by 1.1% during the first quarter. Torray Investment Partners LLC now owns 19,865 shares of the medical research company’s stock worth $1,103,000 after buying an additional 222 shares in the last quarter. Treasurer of the State of North Carolina lifted its position in shares of Natera by 0.7% during the 1st quarter. Treasurer of the State of North Carolina now owns 42,699 shares of the medical research company’s stock valued at $2,371,000 after acquiring an additional 300 shares during the period. Public Employees Retirement System of Ohio raised its holdings in Natera by 0.8% during the third quarter. Public Employees Retirement System of Ohio now owns 43,299 shares of the medical research company’s stock worth $1,897,000 after purchasing an additional 341 shares during the last quarter. Neuberger Berman Group LLC boosted its position in Natera by 0.6% during the first quarter. Neuberger Berman Group LLC now owns 72,533 shares of the medical research company’s stock worth $2,950,000 after purchasing an additional 406 shares in the last quarter. Finally, Machina Capital S.A.S. acquired a new stake in Natera in the first quarter valued at $28,000. 92.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Natera news, insider Jonathan Sheena sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $44.22, for a total transaction of $221,100.00. Following the completion of the sale, the insider now owns 504,746 shares of the company’s stock, valued at $22,319,868.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Daniel Rabinowitz sold 800 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $47.83, for a total value of $38,264.00. Following the completion of the transaction, the insider now directly owns 178,478 shares in the company, valued at $8,536,602.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Sheena sold 5,000 shares of Natera stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $44.22, for a total transaction of $221,100.00. Following the sale, the insider now directly owns 504,746 shares in the company, valued at approximately $22,319,868.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,493 shares of company stock valued at $1,401,628. 9.42% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on NTRA shares. StockNews.com assumed coverage on shares of Natera in a research report on Thursday, August 17th. They issued a “sell” rating on the stock. UBS Group began coverage on Natera in a research report on Friday, May 5th. They set a “buy” rating and a $76.00 price objective for the company. The Goldman Sachs Group dropped their price target on Natera from $70.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, July 21st. Morgan Stanley reduced their price objective on Natera from $72.00 to $70.00 and set an “overweight” rating on the stock in a research report on Monday, August 7th. Finally, Piper Sandler lifted their price objective on Natera from $70.00 to $80.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average price target of $70.22.

Natera Stock Up 3.5 %

Shares of NASDAQ:NTRA opened at $57.38 on Monday. The company has a current ratio of 3.85, a quick ratio of 3.69 and a debt-to-equity ratio of 0.47. The firm has a market cap of $6.58 billion, a price-to-earnings ratio of -11.90 and a beta of 1.18. The stock’s 50-day moving average price is $50.27 and its two-hundred day moving average price is $51.08. Natera, Inc. has a 12-month low of $34.00 and a 12-month high of $59.75.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 3rd. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.12. The business had revenue of $261.40 million for the quarter, compared to analysts’ expectations of $241.67 million. Natera had a negative net margin of 54.97% and a negative return on equity of 88.47%. The company’s quarterly revenue was up 31.9% on a year-over-year basis. During the same period last year, the company earned ($1.50) earnings per share. On average, research analysts forecast that Natera, Inc. will post -4.03 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.